Epidermolysis Bullosa

Krystal Biotech Inc (NASDAQ: KRYS) has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB). DEB is a genetic skin disorder affecting skin and nails that cause...

The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a...

Bank of America's Peter Stapor initiated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ: FOLD) with a price target of $10.00. The leading drug in the company's portfolio is migalastat (Galafold) for a rare disease (Fabry disease), which results in enzyme deficiency and can lead to organ failure...